Memorializes the United States Congress to take action relative to the use of pharmacy benefit managers and their impact on the citizens of this state
House Concurrent Resolution 73 is a memorializing resolution that urges the United States Congress to act on pharmacy benefit managers, or PBMs, and their role in prescription drug pricing and access. The resolution states that PBMs influence drug costs, formularies, rebates, and patient access, and it argues that current PBM practices can increase out-of-pocket costs and limit access to medically necessary medications, especially for seniors, low-income residents, people with chronic conditions, and other vulnerable populations.
The resolution calls for federal action to increase transparency in PBM operations, require rebates and discounts to be passed through to consumers, regulate anti-competitive conduct, strengthen oversight, and limit harmful prior authorization practices. It also asks Louisiana’s congressional delegation to support legislation holding PBMs accountable for harm to patients. As a concurrent resolution, HCR 73 does not change Louisiana statutes directly; instead, it expresses the Legislature’s position and formally transmits that request to Congress and the state’s federal delegation.
HCR 73 has no direct effect on Louisiana state law, criminal law, or regulatory statutes because it is a concurrent resolution rather than a bill amending the Revised Statutes. Its practical impact is political and advocacy-based: it places the Louisiana Legislature on record in support of federal PBM reform and seeks to influence congressional action on drug pricing, transparency, rebates, formularies, and prior authorization practices. The resolution is aimed at patients, insurers, employers, pharmacies, and PBMs operating in prescription drug benefit markets, particularly in Medicaid and other health coverage programs.
The overall sentiment around the resolution appears strongly supportive and reform-oriented. The vote totals show unanimous approval in both chambers, with the House passing it 90-0 and the Senate concurring 36-0. That unanimous support suggests broad agreement that PBM practices are a concern and that federal intervention is needed to improve transparency and consumer protection.
There was no recorded opposition in the voting history and no committee transcript provided, so no specific floor debate or amendment disputes are available. Based on the text, the main policy concerns are PBM pricing practices, rebate retention, formulary restrictions, anti-competitive steering, and delays caused by prior authorization. The resolution frames these as harmful to consumers, while implicitly favoring stronger federal regulation and oversight; any contention would likely center on whether PBMs are a cause of high drug costs and how far Congress should go in regulating their business practices.